Recombinant CD1a antibody (full length)

Catalog No. ABIN7877849

This Mouse Monoclonal antibody specifically detects CD1a in IHC (p). It exhibits reactivity toward Human.

Quick Overview for Recombinant CD1a antibody (full length) (ABIN7877849)

Target: CD1a

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This CD1a antibody is un-conjugated

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: RC1A-8110

Product Details anti-CD1a Antibody

Binding Specificity: full length

Purpose: CD1a Antibody

Purification: Protein A/G affinity

Immunogen: Recombinant full-length human CD1a protein was used as the immunogen for the CD1a antibody.

Isotype: IgG1, kappa

Application Details

Application Notes: Optimal dilution of the CD1a antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.2 mg/mL

Buffer: 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Aliquot the CD1a antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Target Details for CD1a

Target: CD1a

Alternative Name: CD1a

Background: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. Anti-CD1a labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibodies against TTF-1 and CD5, anti-CD1a is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. Anti-CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa).

UniProt: P06126

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process